More on VSQTF

- Summary
- Chart
- Profile
- Historical

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

(OP:VSQTF)
Delayed: 0.34 -0.02 (5.56%)
Prev. Close $0.36  
Open$0.35 
52 Wk High$ 
52 Wk Low$ 
Day High$0.35 
Day Low$0.34 
P/E N/A  
EPS$ 
Volume10,500 

Friends, Peers and Foes (?): VST, NURS, HYDTF, SO6, BCHPY (more...)

Oct 8, 2026 07:30 AM Insu Therapeutics gets U.S. patent allowance for buccal drug delivery
Oct 8, 2026 07:30 AM Insu Therapeutics receives U.S. patent allowance for buccal insulin delivery
Oct 8, 2026 07:30 AM Victory Square Announces U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Platform
Oct 8, 2026 07:30 AM Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology
Oct 6, 2026 08:01 AM Victory Square Technologies Ranks No. 2 Among Publicly Traded Companies on The Globe and Mail's 2026 Canada's Top Growing Companies List
Aug 27, 2026 07:30 AM Hydreight Technologies Announces Timing of Q2 2026 Financial Results and Investor Webcast Featuring Live Analyst Q&A
Jul 29, 2026 08:01 AM Victory Square Provides Update on Hydreight and Healthcare Investments Following FDA Advisory Committee Recommendations on Peptide-Related Bulk Drug Substances
Jul 29, 2026 07:00 AM Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations
Jun 2, 2026 12:05 AM Victory Square Reports Q1 2026 Financial Results and Provides Portfolio Update
Jun 1, 2026 09:32 PM Hydreight Delivers Record First Quarter 2026 Revenue of $24.9 Million with 449% Revenue Growth, $3.3 Million in Adjusted EBITDA² and $32.0 Million in Working Capital
View All Articles

Entities mentioned with VSQTF

View All Entities